After opting in last year, Gilead picks up Kymera's KT-200.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
LY4170156 looks similar to Genmab’s rina-S, but cost Lilly a lot less.
Enhertu plus Perjeta shows a convincing progression-free survival benefit over a Perjeta triplet.
Bristol buys into the frenzy, and VEGF bispecific value inflation continues.
Evopoint reveals intriguing but opaque first-in-human data for XNW27011.
Imdelltra seems headed for full approval, raising questions about Zai’s accelerated plan.
But camizestrant’s use could depend on uptake of monitoring – for now.
